Toxoplasmosis Treatment Drugs Market Report 2026

Toxoplasmosis Treatment Drugs Market Overview

• Toxoplasmosis Treatment Drugs market size has reached to $3.49 billion in 2025 • Expected to grow to $4.66 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Rising Prevalence Of Toxoplasmosis Infections Fueling Growth In The Treatment Drug Market • Market Trend: Strategic Investments In Toxoplasmosis Treatment Drugs Market • North America was the largest region in 2025.

What Is Covered Under Toxoplasmosis Treatment Drugs Market?

Toxoplasmosis treatment drugs refer to medications or pharmaceutical products that manage infectious diseases caused by Toxoplasma gondii. It is used to treat the parasitic infection that results from infection with a common parasite found in cat feces and contaminated food. The main drug class types of toxoplasmosis treatment drugs market are pyrimethamine, spiramycin, leucovorin, sulfadiazine, folic acid, and others. Chronic toxoplasmosis infection refers to a long-term infection caused by the protozoan parasite toxoplasma gondii. The various indications include chronic toxoplasmosis infection and acute toxoplasmosis infection. The various routes of administration include parenteral, and oral and are distributed through various distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Toxoplasmosis Treatment Drugs Market Growth Forecast?

The toxoplasmosis treatment drugs market size is expected to see strong growth in the next few years. It will grow to $4.66 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advancements in precision medicine, rising investment in anti-parasitic drug R&D, expansion of online pharmacies, growing immunocompromised patient population, introduction of novel combination therapies. Major trends in the forecast period include increased research in anti-parasitic drug development, rising demand for combination therapies, growth in pediatric and immunocompromised patient treatments, expansion of hospital and online pharmacy distribution channels, development of oral and parenteral formulations.

Global Toxoplasmosis Treatment Drugs Market Segmentation

1) By Drug Class: Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, Other Drug Class 2) By Indication: Chronic Toxoplasmosis Infection, Acute Toxoplasmosis Infection 3) By Route Of Administration: Parenteral, Oral 4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies Subsegments: 1) By Pyrimethamine: Brand Name Variants, Combination Therapies 2) By Spiramycin: Brand Name Variants, Formulations 3) By Leucovorin: Dosage Forms, Combination Therapies 4) By Sulfadiazine: Brand Name Variants, Combination Therapies 5) By Folic Acid: Supplement Formulations, Combination Products With Other Drugs 6) By Other Drug Class: Atovaquone, Clindamycin, Trimethoprim-Sulfamethoxazole (TMP-SMX), Experimental Or Emerging Therapies

What Is The Driver Of The Toxoplasmosis Treatment Drugs Market?

The rising prevalence of toxoplasmosis infections is expected to propel the growth of the toxoplasmosis treatment drug market going forward. Toxoplasmosis is a generic term for infection and sickness brought on by the protozoan parasite Toxoplasma gondii in humans and animals. Toxoplasmosis infection increases the need for pyrimethamine, spiramycin, and leucovorin drugs used to treat patients with a particular type of toxoplasmosis, which boosts the toxoplasmosis treatment drug market. For instance, in February 2024, according to the data published by the UK Health Security Agency, a UK-based government agency, in the second quarter of 2023, 54 confirmed toxoplasmosis cases were reported, up from 37 cases in the same period of 2022. Therefore, the rising prevalence of toxoplasmosis infections drives the toxoplasmosis treatment drug industry.

Key Players In The Global Toxoplasmosis Treatment Drugs Market

Major companies operating in the toxoplasmosis treatment drugs market are Sanofi SA, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Mylan NV, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals Inc, Lupin Ltd, Alvogen Group Inc, Manus Aktteva Biopharma LLP, Cadila Healthcare Limited, Aurobindo Pharma Limited, Cipla Inc, Torrent Pharmaceuticals Ltd, Intas Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd, Jubilant Life Sciences, Zydus Lifesciences Ltd, Hetero Drugs Limited, Strides Pharma Science Limited, Alkem Laboratories Limited

Global Toxoplasmosis Treatment Drugs Market Trends and Insights

Major companies operating in the toxoplasmosis treatment drugs market are focusing on strategic investments. Strategic investment is an investment made by a company or individual to achieve a long-term objective, such as gaining a competitive advantage, entering a new market, or developing a new technology. For instance, in April 2023, ASTRA Therapeutics, a UK-based drug development company, received funding of CHF 150,000 ($ 173787.15) through this investment. ASTRA Therapeutics intends to develop therapies for parasite diseases like malaria. Cryptosporidiosis and toxoplasmosis harm millions of people worldwide; they are also a major cause of disease and output loss in cattle and agriculture.

What Are Latest Mergers And Acquisitions In The Toxoplasmosis Treatment Drugs Market?

In August 2023, Vyera Pharmaceuticals, LLC, a Switzerland-based pharmaceutical company, entered into an asset purchase agreement with Phoenixus AG for an undisclosed amount. Through this agreement, both firms seek to sell rights to Daraprim a prescription drug that contains pyrimethamine and is used to treat toxoplasmosis when combined with a sulfonamide and Vecamyl is used to treat moderately severe to severe essential hypertension as well as simple cases of malignant hypertension. Phoenixus AG is a Switzerland-based biopharmaceutical company.

Regional Insights

North America was the largest region in the toxoplasmosis treatment drugs market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Toxoplasmosis Treatment Drugs Market?

The toxoplasmosis treatment drug market consists of sales of clindamycin and atovaquone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Toxoplasmosis Treatment Drugs Market Report 2026?

The toxoplasmosis treatment drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the toxoplasmosis treatment drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.